Nordic Nanovector ASA, of Oslo, said it was awarded a grant of up to NOK15 million (US$1.7 million), payable over three years, from the Research Council of Norway’s user-driven research-based innovation program to support the research and development of targeted therapeutics for leukemia and non-Hodgkin lymphoma. The project is focused on development of antibody radionuclide conjugates (ARC) consisting of a chimeric anti-CD37 antibody and a radioactive nuclide as the cytotoxic agent. Nordic Nanovector will construct and investigate ARCs with different payloads that offer the potential to address multiple hematological malignancies. Successful candidates are expected to advance into clinical trials.